sacituzumab
gilead
['sacituzumab', 'breast', 'tropics-02']
 #asco23 tropics-02. sacituzumab g (sg) in er+/her2- metastatic breast ca, randomized trial v. physician's choice. final results. pda improved 5.5 v. 4.5 month. os 14.5 v. 14.2 months. (not significant). benefit in her2 low and her2 0.
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own